Day: July 12, 2020

WALTHAM, Mass., July 12, 2020 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced the poster presentation of data from two Phase 2 randomized, placebo-controlled, dose ranging studies which showed safety and efficacy of ciraparantag reversing the effects of apixaban and rivaroxaban in healthy adults age 50-75 years. The poster, “Efficacy and Safety of Ciraparantag in Reversing Apixaban and Rivaroxaban in Healthy Adults” was accepted for the 2020 International Society on Thrombosis and Haemostasis (ISTH) virtual annual meeting. Ciraparantag is in development for use in patients treated with direct oral anticoagulants (DOACs) and low molecular weight heparin (LMWH) when reversal of the anticoagulant effect of these products is needed for emergency surgery, urgent procedures or due to life-threatening or uncontrolled...

SHANGHAI, China, July 12, 2020 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that following its application to The Stock Exchange of Hong Kong Limited (HKEX) pursuant to Rule 18A.12 of the Rules Governing the Listing of Securities on HKEX (Listing Rules), HKEX has granted approval for the dis-application of Rules 18A.09 to 18A.11 of the Listing Rules. Junshi Biosciences originally listed on the HKEX on December 24, 2018 under Chapter 18 A (the biotech chapter) of the Listing Rules. It now satisfies and even well surpasses the revenue and market capitalization requirements for the dis-application.As a result of the approval by the HKEX, the “B” marker will no longer be affixed...

PRFoods’ unaudited preliminary consolidated turnover in 4th quarter of the fiscal year 2019/2020 amounted to EUR 15.11 million euros, decreased by 29.5% compared to the same period a year ago (4Q 2018/2019: 21.42 million euros). The preliminary turnover of the first 12 months of the financial year was 78.34 million euros (12m 2018/2019: 85.61 million euros).The Q4 decline in sales was 29.5%; including sales increase in retail sector by 7.3%, sales decrease in HoReCa sector by 65.0% and in wholesale sector by 49.6% (partly also influenced by HoReCa sector) compared to the same period previous year;The 12-months sales decrease compared the same period a year ago was 8.5%, mainly affected by lower sales figure in the 4th quarter. During 2019/2020 the product portfolio experienced a change where raw fish and fillets’ segment increased by...

PRFoodsi 2019/2020. aasta neljanda kvartali auditeerimata esialgne konsolideeritud käive oli 15,11 miljonit eurot langedes eelmise aasta sama perioodiga võrreldes 29,5% (4kv 2018/2019: 21,42 miljonit eurot). Majandusaasta 12 kuu esialgne käive oli 78,34 miljonit eurot (12k 2018/2019: 85,61 miljonit eurot).4. kvartali müügilanguseks kujunes 29,5%, sealhulgas müügikasv jaekettides 7,3% ning müügilangus HoReCa sektoris 65,0% ja hulgimüügis 49,6% (osaliselt samuti mõjutatud HoReCa sektorist) võrreldes eelmise aasta sama perioodiga;12 kuu müügilangus kokku võrreldes eelmise aasta sama perioodiga oli 8,5%, millele suurimat mõju avaldas 4.kvartali madalam käive. 2019/2020. aastal toimus muudatus ka tooteportfellis, kus värske kala ja -filee osakaal on suurenenud 4 pp ning suitsutatud toodete osakaal vastavalt vähenenud.Indrek Kasela, PRFoods...

PETAH TIKVA, Israel, July 12, 2020 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (NASDAQ, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, announced that further to its announcement of July 8, 2020, it was notified on July 11, 2020 that an amended complaint was filed by Comtech Telecommunications Corp. and its subsidiary, Convoy Ltd., against Gilat in the Court of Chancery of the State of Delaware. The amended complaint seeks an additional declaratory judgment that Gilat has suffered a “Material Adverse Effect” as defined in the Merger Agreement, as a result of the Covid-19 pandemic and, as a consequence, Comtech is not required to consummate the merger because certain closing conditions of the Merger Agreement cannot be satisfied.Gilat strongly rejects all such allegations. Gilat believes...